Vertex Pharmaceuticals valuation

VRTX · NASDAQ · USD

Compare Vertex Pharmaceuticals
$534.20Change from previous close: −0.67%Absolute change: −$3.59

Close · November 17, 2026

Valuation

The P/E ratio is 34.4. The average price target of 28 analysts is $595.36.

Data as of November 18, 2026

Vertex Pharmaceuticals compared with similar companies

Vertex Pharmaceuticals's P/E (trailing 12 months): 34.4, in line with the median of a group of 7 similar companies (34.4).

Vertex Pharmaceuticals's metrics compared with similar companies
MetricVertex PharmaceuticalsMedian25th–75th percentileBand
P/E (trailing 12 months)34.434.427.0 – 49.1Middle
Forward P/E26.821.013.8 – 31.0Middle
EV/EBITDA26.622.717.0 – 26.1High
Price/book6.487.125.30 – 14.1Middle
Price/sales10.510.36.15 – 17.1Middle
Gross margin54.8%56.0%23.4% – 80.8%Middle
Operating margin37.8%19.5%-61.2% – 32.1%High
Net margin30.7%13.9%0.0% – 29.6%High
ROE20.8%10.0%-28.0% – 17.5%High
Debt/equity0.310.350.05 – 0.73Middle

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

Vertex Pharmaceuticals: valuation over time

On the latest fiscal year's earnings (2025), Vertex Pharmaceuticals's P/E today is 35.0, above the median of its last 8 fiscal years (26.8; between 20.5 and 144.1 from 2017 to 2025). Relative to earnings, the stock costs more than it used to.

Vertex Pharmaceuticals P/E and dividend yield at each fiscal year end
Fiscal yearPrice at year endEarnings per shareP/E
2025$453.36$15.3229.6
2024$402.70-$2.08—
2023$406.89$13.8929.3
2022$288.78$12.8222.5
2021$219.60$9.0124.4
2020$236.34$10.2923.0
2019$218.95$4.5148.5
2018$165.71$8.0920.5
2017$149.86$1.04144.1
2016$73.67-$0.46—

TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only). Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above.

TickerLandia analysisHow it is calculated

Other metrics

Valuation multiples

Market cap
$135.44B
Enterprise value
$135.63B
PEG
2.34
EV/revenue
10.5

Profitability and growth

ROA
10.6%
ROIC
23.1%
Revenue growth (year over year)
11.8%
Earnings growth (year over year)
-39.0%

Financial health

Total cash
$6.3B
Total debt
$6.48B
Current ratio
2.34
Quick ratio
1.72
Altman Z-Score
7.80
Piotroski F-Score
4.00

Dividends

Dividend yield
0.0%
Payout ratio
0.0%

Analysts and estimates

Average price target
$595.36
Median price target
$609.50
High price target
$725.00
Low price target
$350.00
Analysts with a price target
28
Consensus
Buy
Forward EPS
$19.92
EPS estimate, current year
$18.14

Shares and trading

Beta
0.28
Average volume
1.24M
Shares outstanding
253.54M
Float
252.77M
Institutional ownership
98.1%
Insider ownership
0.3%
Short interest (% of float)
2.1%
Short ratio (days)
3.55